SYNTHENA AG

Their core work

SYNTHENA AG is a Bern-based Swiss private company working at the intersection of nucleic acid chemistry and biomedical research. Their participation in MMBio — a project on molecular tools for nucleic acid manipulation and biological intervention — indicates they develop or supply specialized chemical reagents, oligonucleotide analogs, or synthesis tools used in molecular biology research. In the BIND consortium, they contributed EUR 100,000 worth of work to a large collaborative study on brain involvement in Duchenne Muscular Dystrophy, covering gene therapy approaches, deep phenotyping, and animal model studies. Their consistent role as a specialist partner rather than coordinator suggests they operate as a niche supplier or technical service provider that brings specific chemistry capabilities to academic and clinical research programs.

What they specialise in

How they've shifted over time

SYNTHENA entered EU research in 2017 through MMBio with no disease-specific focus — their role there appears to have been as a provider of general molecular tools for nucleic acid manipulation, a foundational chemistry capability. By 2020, their second project (BIND) was firmly anchored in a specific therapeutic application: Duchenne Muscular Dystrophy, gene therapies, and neurological phenotyping. This shift from platform chemistry to rare disease therapeutics is a clear and deliberate narrowing toward high-value clinical applications where oligonucleotide-based tools are directly relevant.

SYNTHENA is moving toward applying nucleic acid chemistry as a direct enabler of gene and antisense therapies for rare neuromuscular and neurological diseases — a field with strong clinical and commercial momentum.

How they like to work

SYNTHENA has never led an H2020 project; in both cases they joined as a partner or third party, which points to an organization that contributes specific technical components rather than designing or managing research programs. Despite only two projects, they engaged with 38 distinct partners across 13 countries, meaning they were embedded in genuinely large international consortia rather than small bilateral arrangements. This profile fits a specialist technology or reagent provider that earns its place in consortia by offering something others cannot easily replicate.

With 38 unique consortium partners across 13 countries from just two projects, SYNTHENA's network reach is disproportionately large relative to their project count, entirely a function of the large multi-partner consortia they joined. Their collaboration geography is broadly European with a Swiss base.

What sets them apart

SYNTHENA occupies a very specific niche: nucleic acid chemistry expertise applied to gene therapy and rare disease research, particularly DMD — a therapeutic area where antisense oligonucleotides and related molecules are a frontline technology. Operating from Bern, they sit within Switzerland's well-established life sciences corridor, which adds credibility and access to pharma partnerships beyond EU project work. With only two EU projects, they are clearly selective about consortia they join, which suggests they bring something concrete and non-generic rather than competing on breadth.

Highlights from their portfolio

• BIND
  SYNTHENA's only funded EU project (EUR 100,000), focused on the neurological dimensions of Duchenne Muscular Dystrophy with gene therapy and deep phenotyping — a high-profile rare disease area with active clinical development worldwide.
• MMBio
  An MSCA training network on nucleic acid manipulation tools, notable as SYNTHENA's entry point into EU consortia and evidence of their foundational chemistry platform before the therapeutic pivot.